ECO 11: Medicines Optimisation in Northern Ireland - Frans van AndelInnovation Agency
Frans introduces the work of the Medicines Optimisation Innovation Centre based in Northern Ireland. He talks about their background; aims and how they achieve them; and current key initiatives. Frans also discusses the ongoing work of MOIC in enabling technology, the pharmaceutical industry, knowledge transfer, training and education, and other key initiatives.
ECO 11: Medicines Optimisation Through Precision - Sir Munir PirmohamedInnovation Agency
Munir Pirmohamed discusses the potential impact of medicines optimisation in terms of ensuring the right patients get the right choice if medicine at the right time. He presents a case history of over prescription and introduces three examples of medicines optimisation through use of genetics, big data, and pharmacogenetics profiling.
ECO 11: Transfer of Care to Pharmacy - Hassan Argomandkhah, Chair of Pharmacy...Innovation Agency
Hassan introduces the concept and key objectives of transfer of care to pharmacy (TCP). The slides include a project outline, an overview of TCP in Cheshire and Merseyside, and the benefits and potential savings of Electronic Transfer of Care to Pharmacy.
Slides from the presentation on extrapolation from progression free survival to overall survival in oncology given at the 2017 HTAi Annual Meeting in Rome
ECO 11: Medicines Optimisation in Northern Ireland - Frans van AndelInnovation Agency
Frans introduces the work of the Medicines Optimisation Innovation Centre based in Northern Ireland. He talks about their background; aims and how they achieve them; and current key initiatives. Frans also discusses the ongoing work of MOIC in enabling technology, the pharmaceutical industry, knowledge transfer, training and education, and other key initiatives.
ECO 11: Medicines Optimisation Through Precision - Sir Munir PirmohamedInnovation Agency
Munir Pirmohamed discusses the potential impact of medicines optimisation in terms of ensuring the right patients get the right choice if medicine at the right time. He presents a case history of over prescription and introduces three examples of medicines optimisation through use of genetics, big data, and pharmacogenetics profiling.
ECO 11: Transfer of Care to Pharmacy - Hassan Argomandkhah, Chair of Pharmacy...Innovation Agency
Hassan introduces the concept and key objectives of transfer of care to pharmacy (TCP). The slides include a project outline, an overview of TCP in Cheshire and Merseyside, and the benefits and potential savings of Electronic Transfer of Care to Pharmacy.
Slides from the presentation on extrapolation from progression free survival to overall survival in oncology given at the 2017 HTAi Annual Meeting in Rome
Mr James Downie, CEO, presented on the topic 'Moving towards value based funding' at the Healthcare reform, funding and innovation conference, hosted by AventEdge on 27 June 2017.
In a research report by Berdud, M., Drummond, M. and Towse, A. (2018), a reasonable price for an orphan drug was established based on the proposition that rates of returns from investments in developing orphan drugs should be no greater than the industry average (for all drugs). At the 2018 EuHEA conference held in Maastricht, The Netherlands, 11-14 July, Mikel showed (i) how the reasonable price should be established and (ii) how NICE's cost-effectiveness threshold should be adjusted to ensure a reasonable price for an orphan drug. In slides results are discussed and conclusions showed too.
Author(s) and affiliation(s): Mikel Berdud, PhD (OHE); Prof. Mike Drummond (University of York); Prof. Adrian Towse (OHE)
Conference/meeting: EuHEA 2018
Location: Maastricht, The Netherlands
Date: 12/07/2018
The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public...Office of Health Economics
This project seeks to elicit the public’s preferences for different features of a genomic test to sequence advanced solid cancer tumours. Understanding the relative preferences for various attributes of targeted testing are useful for determining the value of sequencing approaches, and informing technology adoption decisions. A discrete choice experiment (DCE) survey was designed to assess the preferences of members of the Australian general public for targeted sequencing in advanced cancer. The survey presented respondents with 12 questions in which they had to choose between two unlabelled tests (Test A and Test B). Tests were specified in terms of five attributes: time to receive the test result; cost of the test; likelihood that the test result will lead to a change in treatment; length of time health care professionals spend describing the test; and type of health care team who explains the test result. Respondents were sampled from an online panel and also completed questions related to demographic and socio-economic factors, experiences of cancer and familial history. We found that cost, timeliness, expertise/location and likeliness of changing treatment regimes were identified as attributes of genomic sequencing that are most valuable to a sample of the public. These results will ultimately be compared with the results of an ongoing DCE being conducted with patients with advanced cancer who are undergoing sequencing.
Author(s) and affiliation(s): Paula Lorgelly (OHE), Grace Hampson (OHE), James Buchanan (Oxford), Melissa Martyn (MGHA), Jayesh Desai (PeterMac), Clara Gaff (MGHA), and iPREDICT MGHA Flagship collaborators
Conference/meeting: EuHEA 2018
Location: Maastricht, the Netherlands
Date: 12/07/2018
Effects of the 2016 pharmaceutical reimbursement scheme changes – a microsimu...TITA research
Aaltonen, Heino, Ahola & Martikainen: Effects of the 2016 pharmaceutical reimbursement scheme changes – a microsimulation study. Presentation at TITA Annual Research Meeting 15.-16.9.2016.
Does patient engagement result in more appropriate utilization?Benjamin Littenberg
This presentation reviews what published research has established about how patient engagement improves the overall clinical experience and what that means for providers.
Presentation delivered by Mr Shaun Flanagan, Corporate Pharmaceutical Unit, Health Service Executive at the Irish Pharmaceutical Healthcare Association Annual Meeting 2009.
Mr James Downie, CEO, presented on the topic 'Emergency care costing study and classification development' at the 9th Annual Emergency Department Management Conference, hosted by informa on 31 July 2017.
Evaluation of the Hepa Wash treatment in pigs with acute liver failureEnrique Moreno Gonzalez
Mortality of patients with acute liver failure (ALF) is still unacceptably high. Available liver
support systems are still of limited success at improving survival. A new type of albumin
dialysis, the Hepa Wash® system, was newly introduced. We evaluated the new liver support
system as well as the Molecular Adsorbent Recycling System (MARS) in an ischemic
porcine model of ALF.
Mr James Downie, CEO, presented on the topic 'Moving towards value based funding' at the Healthcare reform, funding and innovation conference, hosted by AventEdge on 27 June 2017.
In a research report by Berdud, M., Drummond, M. and Towse, A. (2018), a reasonable price for an orphan drug was established based on the proposition that rates of returns from investments in developing orphan drugs should be no greater than the industry average (for all drugs). At the 2018 EuHEA conference held in Maastricht, The Netherlands, 11-14 July, Mikel showed (i) how the reasonable price should be established and (ii) how NICE's cost-effectiveness threshold should be adjusted to ensure a reasonable price for an orphan drug. In slides results are discussed and conclusions showed too.
Author(s) and affiliation(s): Mikel Berdud, PhD (OHE); Prof. Mike Drummond (University of York); Prof. Adrian Towse (OHE)
Conference/meeting: EuHEA 2018
Location: Maastricht, The Netherlands
Date: 12/07/2018
The Value of Targeted Sequencing in Advanced Cancer: DCE to Elicit the Public...Office of Health Economics
This project seeks to elicit the public’s preferences for different features of a genomic test to sequence advanced solid cancer tumours. Understanding the relative preferences for various attributes of targeted testing are useful for determining the value of sequencing approaches, and informing technology adoption decisions. A discrete choice experiment (DCE) survey was designed to assess the preferences of members of the Australian general public for targeted sequencing in advanced cancer. The survey presented respondents with 12 questions in which they had to choose between two unlabelled tests (Test A and Test B). Tests were specified in terms of five attributes: time to receive the test result; cost of the test; likelihood that the test result will lead to a change in treatment; length of time health care professionals spend describing the test; and type of health care team who explains the test result. Respondents were sampled from an online panel and also completed questions related to demographic and socio-economic factors, experiences of cancer and familial history. We found that cost, timeliness, expertise/location and likeliness of changing treatment regimes were identified as attributes of genomic sequencing that are most valuable to a sample of the public. These results will ultimately be compared with the results of an ongoing DCE being conducted with patients with advanced cancer who are undergoing sequencing.
Author(s) and affiliation(s): Paula Lorgelly (OHE), Grace Hampson (OHE), James Buchanan (Oxford), Melissa Martyn (MGHA), Jayesh Desai (PeterMac), Clara Gaff (MGHA), and iPREDICT MGHA Flagship collaborators
Conference/meeting: EuHEA 2018
Location: Maastricht, the Netherlands
Date: 12/07/2018
Effects of the 2016 pharmaceutical reimbursement scheme changes – a microsimu...TITA research
Aaltonen, Heino, Ahola & Martikainen: Effects of the 2016 pharmaceutical reimbursement scheme changes – a microsimulation study. Presentation at TITA Annual Research Meeting 15.-16.9.2016.
Does patient engagement result in more appropriate utilization?Benjamin Littenberg
This presentation reviews what published research has established about how patient engagement improves the overall clinical experience and what that means for providers.
Presentation delivered by Mr Shaun Flanagan, Corporate Pharmaceutical Unit, Health Service Executive at the Irish Pharmaceutical Healthcare Association Annual Meeting 2009.
Mr James Downie, CEO, presented on the topic 'Emergency care costing study and classification development' at the 9th Annual Emergency Department Management Conference, hosted by informa on 31 July 2017.
Evaluation of the Hepa Wash treatment in pigs with acute liver failureEnrique Moreno Gonzalez
Mortality of patients with acute liver failure (ALF) is still unacceptably high. Available liver
support systems are still of limited success at improving survival. A new type of albumin
dialysis, the Hepa Wash® system, was newly introduced. We evaluated the new liver support
system as well as the Molecular Adsorbent Recycling System (MARS) in an ischemic
porcine model of ALF.
- Recorded videos of the lecture:
English Language version of this lecture is available at: https://youtu.be/-Ynxvhbcl7U
Arabic Language version of this lecture is available at: https://youtu.be/QpK_toctVlw
- Visit our website for more lectures: www.NephroTube.com
- Subscribe to our YouTube channel: www.youtube.com/NephroTube
- Join our facebook group: www.facebook.com/groups/NephroTube
- Like our facebook page: www.facebook.com/NephroTube
- Follow us on twitter: www.twitter.com/NephroTube
Prof Angela Timoney
Presentation at EIPG - Royal Pharmaceutical Society Scientific Symposium "Advances in Technology Impacting the Pharmaceutical Industry" at the University of Strathclyde, Glasgow 2015.
Medical Related information reconciliation when a patient sees many providers or transfers between health facilities is challenging. Lack of updated and correct information is a key concern for patient safety during a health and illness trajectory [1]. Errors, near misses and adverse medication events are too common, particularly whne transfers between hospitals, nursing home and home are frequent, or engagement of multiple specialties is common [2]. Lack of effective informatics support can be harmful to a person’s health, leading to suffering, increased use of health care resources and increased costs.
As a case for interactive discussion, we have chosen information exchanges related to medication, prescription-based as well as over the counter drugs. This challenging chain of activities includes: (a) prescribing on paper or electronically by several medical specialists, (b) transcribing by sending and interpreting prescriptions in the pharmacy, (c) dispensing medication by brand name or generic substitution, (d) acquiring over the counter medication, (e) administering medication as a user, and (f) observing effects and side-effects. The risk of missing information leading to mistakes in the chain of activities in medication management is likely to increase as complex medication regimes become common due to demographic developments, co-morbidities or more personalized treatment. Potentials in patient activation and relevant informatics tools for medication reconciliation need further exploration.
Anne MOEN Institute for Health and Society, Faculty of Medicine, University of Oslo, NORWAY
Catherine CHRONAKI HL7 Foundation, Brussels, BELGIUM
Christian NØHR, Aalborg University, DENMARK
Line Helen LINSTAD Norwegian Center for eHealth Research, Tromsø, NORWAY
Petter HURLEN Akershus University Hospital, NORWAY
Ομιλία – Παρουσίαση: Raymond Anderson, President Commonwealth Pharmaceutical Association and Member of the Pharmacovigilance Risk Assessment Committee (PRAC) at EMA
«Best Practices to inform citizens on Self-medication»
Outcome Measures in Cancer: Do disease specific instruments offer greater sen...Office of Health Economics
Paula's slides for her presentation on Outcomes Measures in Cancer given at the C2E2 Rounds Conference at the University of British Columbia on July 5th, 2017.
Opening Keynote"From Patient to Population: Providing Optimal Care - The Role for Technology"
Ronald Paulus, MD, MBA
President & CEO
Mission Health System
Slides from the workshop 'A modern vision of integrated care and support' led by Dr Martin McShane, Dr Damian Riley (NHS England) and David Pearson (ADASS) - NHS Medical Leaders Conference 2014. - See more at: http://www.icase.org.uk/pg/cv_content/content/view/98680#sthash.45Xs2o9r.dpuf
Introduction of the NZ Health IT Plan enables better gout management - Reflections of an early adopter. Presented by Peter Gow, Counties Manukau DHB, at HINZ 2014, 12 November 2014, 11.37am, Plenary Room
ICN Victoria presents Dr Dashiell Gantner, research fellow at the Monash University in Melbourne. Here he talks about translating ICU research into clinical practice.
MicroGuide app, pop up uni, 1pm, 3 september 2015NHS England
Expo is the most significant annual health and social care event in the calendar, uniting more NHS and care leaders, commissioners, clinicians, voluntary sector partners, innovators and media than any other health and care event.
Expo 15 returned to Manchester and was hosted once again by NHS England. Around 5000 people a day from health and care, the voluntary sector, local government, and industry joined together at Manchester Central Convention Centre for two packed days of speakers, workshops, exhibitions and professional development.
This year, Expo was more relevant and engaging than ever before, happening within the first 100 days of the new Government, and almost 12 months after the publication of the NHS Five Year Forward View. It was also a great opportunity to check on and learn from the progress of Greater Manchester as the area prepares to take over a £6 billion devolved health and social care budget, pledging to integrate hospital, community, primary and social care and vastly improve health and well-being.
More information is available online: www.expo.nhs.uk
Seeking value: Experience from the UK's National Institute for Health and Car...OECD Governance
This presentation was made by Tommy Wilkinson, United-Kingdom, at the 4th meeting of the Joint DELSA/GOV-SBO Network on Fiscal Sustainability of Health Systems, held in Paris on 16-17 February 2015.
Slides from the Strategic Clinical Network, Cardiovascular Disease Network meeting on 16 January 2015.
The event was run by the Living Longer Lives programme and covers the work we’re doing to implement the Department of Health’s CVD Outcomes strategy, including improving the physical health of people with serious mental illness, supporting the NHS Health Check programme and the GRASP suite of audit tools.
How can patients and providers best contribute to the HTA process?EUnetHTA
How can patients and providers best contribute to the HTA process? Anna Nachtnebel, LBI-HTA, Simone Warren, ZIN
Presentation from the 3rd face to face training course for EUnetHTA Stakeholders organised by EUnetHTA JA2 WP2; April 23rd, 2015, Brussels.
How to use the EUnetHTA submission template to support production of core Hea...EUnetHTA
How to use the EUnetHTA submission template to support production of core Health Technology Assessments? Zoe Garrett, NICE
Presentation from the 3rd face to face training course for EUnetHTA Stakeholders organised by EUnetHTA JA2 WP2; April 23rd, 2015, Brussels.
Brief Introduction to the HTA Core Model (r), Anna Nachtnebel, LBI-HTA
Presentation from the 3rd face to face training course for EUnetHTA Stakeholders organised by EUnetHTA JA2 WP2; April 23rd, 2015, Brussels.
How to use HTA for decision-making based on HTA Core InformationEUnetHTA
How to use HTA for decision-making based on HTA Core Information, Anna Nachtnebel, LBI-HTA, Simone Warren, ZIN
Presentation from the 3rd face to face training course for EUnetHTA Stakeholders organised by EUnetHTA JA2 WP2; April 23rd, 2015, Brussels.
Brief introduction to EUnetHTA and its toolsEUnetHTA
Brief introduction to EUnetHTA and its Tools, Marianne Klemp, NOKC
Presentation from the 3rd face to face training course for EUnetHTA Stakeholders organised by EUnetHTA JA2 WP2; April 23rd, 2015, Brussels.
Pulmonary Thromboembolism - etilogy, types, medical- Surgical and nursing man...VarunMahajani
Disruption of blood supply to lung alveoli due to blockage of one or more pulmonary blood vessels is called as Pulmonary thromboembolism. In this presentation we will discuss its causes, types and its management in depth.
Flu Vaccine Alert in Bangalore Karnatakaaddon Scans
As flu season approaches, health officials in Bangalore, Karnataka, are urging residents to get their flu vaccinations. The seasonal flu, while common, can lead to severe health complications, particularly for vulnerable populations such as young children, the elderly, and those with underlying health conditions.
Dr. Vidisha Kumari, a leading epidemiologist in Bangalore, emphasizes the importance of getting vaccinated. "The flu vaccine is our best defense against the influenza virus. It not only protects individuals but also helps prevent the spread of the virus in our communities," he says.
This year, the flu season is expected to coincide with a potential increase in other respiratory illnesses. The Karnataka Health Department has launched an awareness campaign highlighting the significance of flu vaccinations. They have set up multiple vaccination centers across Bangalore, making it convenient for residents to receive their shots.
To encourage widespread vaccination, the government is also collaborating with local schools, workplaces, and community centers to facilitate vaccination drives. Special attention is being given to ensuring that the vaccine is accessible to all, including marginalized communities who may have limited access to healthcare.
Residents are reminded that the flu vaccine is safe and effective. Common side effects are mild and may include soreness at the injection site, mild fever, or muscle aches. These side effects are generally short-lived and far less severe than the flu itself.
Healthcare providers are also stressing the importance of continuing COVID-19 precautions. Wearing masks, practicing good hand hygiene, and maintaining social distancing are still crucial, especially in crowded places.
Protect yourself and your loved ones by getting vaccinated. Together, we can help keep Bangalore healthy and safe this flu season. For more information on vaccination centers and schedules, residents can visit the Karnataka Health Department’s official website or follow their social media pages.
Stay informed, stay safe, and get your flu shot today!
The prostate is an exocrine gland of the male mammalian reproductive system
It is a walnut-sized gland that forms part of the male reproductive system and is located in front of the rectum and just below the urinary bladder
Function is to store and secrete a clear, slightly alkaline fluid that constitutes 10-30% of the volume of the seminal fluid that along with the spermatozoa, constitutes semen
A healthy human prostate measures (4cm-vertical, by 3cm-horizontal, 2cm ant-post ).
It surrounds the urethra just below the urinary bladder. It has anterior, median, posterior and two lateral lobes
It’s work is regulated by androgens which are responsible for male sex characteristics
Generalised disease of the prostate due to hormonal derangement which leads to non malignant enlargement of the gland (increase in the number of epithelial cells and stromal tissue)to cause compression of the urethra leading to symptoms (LUTS
ARTIFICIAL INTELLIGENCE IN HEALTHCARE.pdfAnujkumaranit
Artificial intelligence (AI) refers to the simulation of human intelligence processes by machines, especially computer systems. It encompasses tasks such as learning, reasoning, problem-solving, perception, and language understanding. AI technologies are revolutionizing various fields, from healthcare to finance, by enabling machines to perform tasks that typically require human intelligence.
Prix Galien International 2024 Forum ProgramLevi Shapiro
June 20, 2024, Prix Galien International and Jerusalem Ethics Forum in ROME. Detailed agenda including panels:
- ADVANCES IN CARDIOLOGY: A NEW PARADIGM IS COMING
- WOMEN’S HEALTH: FERTILITY PRESERVATION
- WHAT’S NEW IN THE TREATMENT OF INFECTIOUS,
ONCOLOGICAL AND INFLAMMATORY SKIN DISEASES?
- ARTIFICIAL INTELLIGENCE AND ETHICS
- GENE THERAPY
- BEYOND BORDERS: GLOBAL INITIATIVES FOR DEMOCRATIZING LIFE SCIENCE TECHNOLOGIES AND PROMOTING ACCESS TO HEALTHCARE
- ETHICAL CHALLENGES IN LIFE SCIENCES
- Prix Galien International Awards Ceremony
Report Back from SGO 2024: What’s the Latest in Cervical Cancer?bkling
Are you curious about what’s new in cervical cancer research or unsure what the findings mean? Join Dr. Emily Ko, a gynecologic oncologist at Penn Medicine, to learn about the latest updates from the Society of Gynecologic Oncology (SGO) 2024 Annual Meeting on Women’s Cancer. Dr. Ko will discuss what the research presented at the conference means for you and answer your questions about the new developments.
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Ve...kevinkariuki227
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
TEST BANK for Operations Management, 14th Edition by William J. Stevenson, Verified Chapters 1 - 19, Complete Newest Version.pdf
These simplified slides by Dr. Sidra Arshad present an overview of the non-respiratory functions of the respiratory tract.
Learning objectives:
1. Enlist the non-respiratory functions of the respiratory tract
2. Briefly explain how these functions are carried out
3. Discuss the significance of dead space
4. Differentiate between minute ventilation and alveolar ventilation
5. Describe the cough and sneeze reflexes
Study Resources:
1. Chapter 39, Guyton and Hall Textbook of Medical Physiology, 14th edition
2. Chapter 34, Ganong’s Review of Medical Physiology, 26th edition
3. Chapter 17, Human Physiology by Lauralee Sherwood, 9th edition
4. Non-respiratory functions of the lungs https://academic.oup.com/bjaed/article/13/3/98/278874
MANAGEMENT OF ATRIOVENTRICULAR CONDUCTION BLOCK.pdfJim Jacob Roy
Cardiac conduction defects can occur due to various causes.
Atrioventricular conduction blocks ( AV blocks ) are classified into 3 types.
This document describes the acute management of AV block.
Anti ulcer drugs and their Advance pharmacology ||
Anti-ulcer drugs are medications used to prevent and treat ulcers in the stomach and upper part of the small intestine (duodenal ulcers). These ulcers are often caused by an imbalance between stomach acid and the mucosal lining, which protects the stomach lining.
||Scope: Overview of various classes of anti-ulcer drugs, their mechanisms of action, indications, side effects, and clinical considerations.
4. Case 1:
Hospital policies on liver dialysis
New device to treat liver failure: MARS®
(molecular adsorbents recirculating system)
Life-saving for certain cases of liver failure
Acute toxications (ALF)
Acute-on-chronic liver failure (AoCLF)
Bridging treatment when waiting for transplant
Should all central hospitals provide MARS®?
Merchants marketing actively
4
5. The MUMM program
Managed Uptake of Medical Methods
Joint program of all central hospitals in Finland + Finohta
Topics collected & selected twice yearly
Rapid HTAs (3-9 months) from Finohta
Reviewed & published in FMJ
MUMM Board decision on implementing technology
+ agreement on division of labour
5
6. Liver dialysis: Effect and cost
HTA (original systematic review)
7 RCTs (n = 230), 20 case series (n = 860)
Survival with conservative treatment 0 - 40%, with
MARS® 16 - 100%
Cost: Machine 18 000 €, filter 3 000 € (1/day)
High expertise required
In Finland 30 - 50 eligible patients per year
6
7. MUMM Policy decision on MARS®
National criteria for patient
selection
Close collaboration with
liver transplant unit
necessary
Treatment in one university
hospital (+2 backup)
Patient register & regular
reports of results
↓
A PhD thesis started on the
topic including CEA
7
9. Obesity surgery
•
•
•
•
MUMM suggestion in 2007
Important topic, spreading unevenly
Scoping: Major ethical issues
SII also asked for an HTA
→ Full HTA as basis for policies
• Effectiveness, safety, cost, ethical, social,
organisational and legal issues
9
10.
11. Policy options
No operations (0-option)
1. Strict criteria: 1500 operations /year
2. International criteria, low demand: 3000/yr
3. International criteria, high demand: 6000/yr
Decision for payers
11
12. Each scenario considers
• Effects on health care system
• Effects on health
• Cost impact
• Focal points of
policy discussion
Scenario 2
12
13. Scenario 2 items
•
•
•
•
•
•
•
75 000 persons with morbid obesity
Willing and suitable for operation: 13 000
Spread over 5 years: 3000 operations yearly
Personnel need for operations: 105 py
Increased demand for treatment abroad /privately
10-20 operation induced deaths yearly
400 complications, 300 reoperations /yr
13
14. Prioritisation by point system
1. Strict criteria
BMI > 45: 50 pts
BMI 40-45: 40 pts
BMI 35-40: 30 pts
BMI points
2. International criteria
BMI > 40: 50 pts
BMI 35-40: 40 pts
Other points
Type 2 diabetes: 20 pts
Any other disease that
Medicated hypertension: 10 pts
obesity aggravates: 10 pts
Sleep apnea w. CPAP: 10 pts
Joint problem needing operation: 10 pts
50 points: Operation indicated
14
15. How does this translate to policy?
• Ministry decision on
criteria for elective
operations
• Social insurance
decision on coverage
Same principles for
public and private care
15
16. Two successful examples -why?
Policy making structures in place
Clear customers for HTA report
Inclusive process of HTA and decision making
Collaboration and mutual trust between decision
makers, clinicians and methodologists
Sufficiently rapid reply - patience to wait for it
16
17. Evidence into
decisions:
Barriers
Policy makers ask wrong
questions
Researchers aim at
perfect answers
They disagree on timing
→ Need to develop a
shared understanding
of HTA use in policy
17
18. Policy implementation:
a major challenge
HTA producers provide data, not policies
May participate in policy formation as
experts
Post HTA report implementation: national
seminar, participation in formulating legislation,
national training, producing patient leaflets, web
learning materials, effect assessment...
18